NURO NeuroMetrix, Inc. featured news, full reports, and detailed charts
NeuroMetrix, Inc. (NURO) Wrap Up:
We design, develop and market proprietary medical devices used to help physicians diagnose and treat diseases of the nervous system such as neuropathies, which are disorders of the peripheral nerves and parts of the spine, and neurovascular disorders such as diabetic retinopathy. We are also developing medical devices designed to be used to provide regional anesthesia and pain control. To date, our focus has been on products that help physicians with the diagnosis or detection of neuropathies and neurovascular disorders. We have two product lines cleared by the United States Food and Drug Administration, or FDA, that are currently being marketed primarily to physicians and clinics, including the NC-stat System for the assessment of neuropathies and the DigiScope for the detection of eye disorders such as diabetic retinopathy. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f14%2f0001047469-08-002829.html#FIS_BUSINESS"NeuroMetrix Inc. (NURO:NASDAQ)
Snapshot of NeuroMetrix Inc. (NURO)
|
OPEN
$2.53
|
PREVIOUS CLOSE
$2.55
|
|
|
DAY HIGH
$2.58
|
DAY LOW
$2.48
|
|
|
52 WEEK HIGH
09/11/09 - $3.60
|
52 WEEK LOW
11/21/08 - $0.52
|
|
|
MARKET CAP
57.6M
|
AVERAGE VOLUME 3 mo
27.4K
|
|
|
DILUTED EPS TTM
$-1.11
|
SHARES OUTSTANDING
23.0M
|
|
|
NURO Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
NURO Top Compensated Officers
Executives, Board Directors
Key developments for NeuroMetrix Inc. (NURO)
NeuroMetrix Inc. reported consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported loss from operations of $1,923,963, loss from continuing operations of $9,263,460 and net loss of $9,263,460 or $0.57 per share on total revenue of $6,325,951, compared to loss from operations of $2,317,628, loss from continuing operations of $2,310,161 and net loss of $7,852,147 or $0.57 per share on total revenue of $7,077,238 for the same period last year. For the nine months, the company reported loss from operations of $5,077,551, loss from continuing operations of $12,280,731 and net loss of $12,280,731 or $0.84 per share on total revenue of $19,911,948, compared to loss from operations of $15,157,466, loss from continuing operations of $16,634,829 and net loss of $23,587,602 or $1.72 per share on total revenue of $23,940,729 for the same period last year.
NeuroMetrix Inc., Q3 2009 Earnings Call, Nov-05 2009
NeuroMetrix Inc. announced the appointment of Thomas T. Higgins as Senior Vice President and Chief Financial Officer. The appointment is effective immediately. Prior to joining the company, Mr. Higgins was Executive Vice President and Chief Financial Officer at Caliper Life Sciences. Inc. during the period starting in 2005.
NURO Competitors
| Company | Last | Change |
| AtriCure Inc | $5.86 USD | +0.075 |
| Banyan Corp | $0.0001 USD | 0.00 |
| Hansen Medical Inc | $2.70 USD | +0.05 |
| NMT Medical Inc | $1.84 USD | 0.0001 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | NURO | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 1.5x |
|
| Price/Book | 2.7x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.9x |
|
|
NURO |
||
NURO transactions
| Type Date |
Target |
|
Private Placement
September 8, 2009 |
-- |